ReviewFrontiers in medicine2026
Endoscopic ultrasound-guided radiofrequency ablation for pancreatic cystic neoplasms: a comprehensive review.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection of pancreatic cystic lesions (PCLs) is increasingly common, with certain subtypes like intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN) carrying malignant potential. Current management, based on risk-stratified guidelines, faces challenges including imperfect specificity of high-risk features, surgical overtreatment, and the burden of long-term surveillance. For high-risk patients unfit for surgery, the traditional surgery or surveillance paradigm is inadequate, driving the need for minimally invasive therapies. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) merges precise targeting with thermal ablation, emerging as a promising local treatment option for PCLs. This review aims to systematically explore the technical principles, device evolution, and standardized operational procedures of EUS-RFA. It will provide a detailed analysis of its current clinical application status, efficacy, and safety evidence across different pathological types of PCLs, and highlight its unique advantages and applicable scenarios through a comparative analysis with EUS-guided chemical ablation. Finally, this article will examine the current challenges facing this technology and prospect its future development directions. Comprehensive existing evidence suggests that EUS-RFA has evolved from a prospective technology into an important therapeutic option characterized by high efficacy, safety, and minimal invasiveness for carefully selected PCLs with malignant potential. However, the full establishment of its clinical value still relies on the accumulation of higher-level evidence-based data and further standardization in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.